Long-term outcomes of imatinib in patients with FIP1L1/PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China

BACKGROUND: The FIP1L1/PDGFRA (F/P) fusion gene is the most common clonal genetic abnormality of chronic eosinophilic leukemia (CEL). Tyrosine kinase inhibitors (TKI), such as imatinib, have been demonstrated to be effective therapies for F/P mutated disease. The aim of this study was to analyze the...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Shi-Qiang, Qin, Tie-Jun, Xu, Ze-Feng, Zhang, Yue, Ai, Xiao-Fei, Li, Bing, Zhang, Hong-Li, Fang, Li-Wei, Pan, Li-Juan, Hu, Nai-Bo, Xiao, Zhi-Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078089/
https://www.ncbi.nlm.nih.gov/pubmed/27120808
http://dx.doi.org/10.18632/oncotarget.8906

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078089/
https://www.ncbi.nlm.nih.gov/pubmed/27120808
http://dx.doi.org/10.18632/oncotarget.8906

Ejemplares similares